Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

NewsGuard 100/100 Score
May 5 2011

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, today announced that data from a clinical study of PRM-151 (recombinant human Pentraxin-2 (PTX-2)) will be presented at the 2011 American Thoracic Society International Conference (ATS 2011), being held May 13-18, 2011 in Denver, CO.

The poster presentation includes clinical data from a completed Phase 1 study of PRM-151 that evaluated comprehensive safety endpoints and exploratory biomarker activity in healthy subjects and IPF patients. The data to be presented highlight the safety, tolerability, and biomarker activity of Pentraxin-2 therapeutics in patients with idiopathic pulmonary fibrosis (IPF).

Source: Promedior, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Exploring the versatile roles of tissue macrophages beyond immune defense
Microplastics and nanoplastics could be harming your heart health
Vaccines targeting chronic diseases show promise in combatting age-related conditions
Study suggests iron accumulation plays a central role in senescence and fibrosis
UVA scientists develop new approach to machine learning for identifying heart drug
Unraveling the complexities of muscle repair in diabetes: A call for targeted research and therapies
The crucial need for ongoing COVID-19 booster vaccination in vulnerable populations
From Mount Everest to your liver: The alarming reach of 'forever chemicals' in our environment and health

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Dietary carotenoids may reduce risk of non-alcoholic fatty liver disease, study suggests